Engineered Bacterium Thins Lung Biofilms in Pigs
Inhaled living medicine reduced drug-resistant Pseudomonas aeruginosa biofilms in pig airways, researchers report in eBioMedicine.
Updated on Nov. 12, 2026 in Life Sciences

Researchers tested an engineered bacterium that thinned drug-resistant Pseudomonas aeruginosa biofilms in pig lungs, according to a study published in eBioMedicine. The treatment is inhaled through a nebuliser and has previously been shown to tackle biofilms in mice.
Why it matters
Antibiotics given through a drip struggle to penetrate biofilms, which can cause recurring infections in the lungs. A treatment delivered directly through the lung could offer a new approach to infections that resist standard drugs.
The study measured biofilm thickness inside breathing tubes in pigs, which fell from 6.08 to 3.67 micrometres, a reduction of around 40%. P. aeruginosa causes about 1 in 4 cases of ventilator-associated pneumonia, but how these pig results will translate to human patients remains untested.
The players
eBioMedicine
A peer-reviewed open-access journal published by The Lancet that publishes biomedical research across a wide range of disciplines.
The details
The engineered bacterium is Mycoplasma pneumoniae, modified to be harmless to humans and loaded with genes that dissolve the sugars holding a biofilm together, along with toxins that target P. aeruginosa. Because the treatment delivers its molecules through the lung, it is designed to act without causing damage to the airway.
Timeline
Study published in eBioMedicine on November 12, 2026.
The Big Picture
The study extends earlier mouse experiments with the same engineered-bacterium approach into pigs, whose airways are closer in size and structure to human lungs. It marks a step toward using living microbes as delivery vehicles for drugs that conventional antibiotics cannot reach inside biofilms.
If the approach proves safe and effective in people, it could eventually offer patients with chronic or ventilator-linked lung infections a treatment delivered by nebuliser rather than a long intravenous course. For now, the findings remain at the animal-research stage and do not change current treatment options.
The takeaway
Living-medicine research is still early, but it points to a new way of reaching bacteria hidden inside biofilms, a problem that standard drugs often fail to solve. Progress will depend on human safety trials.
Further reading
Explore more on Life Sciences research and how microbes are being engineered for medicine.







